ArticleDiscover oncology2025
GALNT6 associated with O-GlcNAcylation contributes to the tumorigenesis of oral squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensively exploring the roles of MAGEA1 in cryptorchidism and its related transcription factor regulatory network.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWe aimed to explore the regulatory gene associated with O-GlcNAcylation in oral squamous cell carcinoma (OSCC) and the underlying mechanism.
methodsThe publicly available gene expression datasets (GSE23558 and GSE25099) were downloaded from Gene Expression Omnibus database. Differentially expressed genes (DEGs) between tumor and controls were identified by limma package. O-GlcNAcylation related genes with differential expression were screened and filtered by LASSO, RF and SVM machine learning models. The expression of one key gene (GALNT6) was validated in OSCC cells by qRT-PCR assay. Immunohistochemistry staining was used to detect the expression of GALNT6 in clinical tissue samples. GALNT6 expression was knocked down by siRNA transfection. CCK8, cell clone, cell scratch assays and transwell assay were employed to examine the proliferation, migration and invasion ability of OSCC cells.
resultsTotal 16 O-GlcNAcylation-related genes were found to be differentially expressed in OSCC, which were significantly enriched in glycosylation. Four key genes (MUC15, ADAMTS12, GALNT6 and FUT6) were identified with promising prognostic value by three machine learning algorithms. GALNT6 were aberrantly upregulated in OSCC cells and tissues. After GALNT6 knockdown, the cell viability, colony formation, and wound healing ability were obviously reduced, in parallel with suppressed metastasis ability in OSCC cells.
conclusionGALNT6 associated with O-GlcNAcylation is overexpressed in OSCC and its knockdown inhibits the growth of OSCC in vitro.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.